Keywords: GlaxoSmithKline, USA, Tykerb, Lamictal, Approval, Breast cancer, Epilepsy, Employment,

US FDA clears new uses for two GlaxoSmithKline drugs; Tykerb and Lamictal; GSK set to announce 3,000 job cuts

Article | 01 February 2010

Print This

UK drug giant GlaxoSmithKline received two pieces of good news from the US Food and Drug Administration last Friday related ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in